Soňa Balogová, Lucia Noskovičová, Marika Vereb, Lucia Kaliská
In prostate cancer (PCa), similarly as in other malignancies, the exact staging of the disease is essential for optimal
choice of therapeutic regimen. At initial staging, serum PSA levels contribute to evaluation of metastatic risk of PCa
and after initial treatment, they warn about the presence of residual or recurrent disease. However, serum PSA levels
do not inform about localisation of PCa lesions.
Hybrid functional/morphologic PET/CT imaging with appropriate tracer permits a sensitive detection of PCa lesions on
a whole-body level. Three registered radiopharmaceuticals are available for PET/CT in PCa: sodium fluoride (18F), fluorodeoxyglucose
(FDG) and fluorocholine (FCH); the aim of the present article is to provide a basic overview on their clinical
use in PCa.